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A data-driven network model of primary myelofibrosis:
transcriptional and post-transcriptional alterations in
CD34+ cells
E Calura1,6, S Pizzini1,2,6, A Bisognin3, A Coppe3, G Sales1, E Gaffo3, T Fanelli4, C Mannarelli4, R Zini5, R Norfo5, V Pennucci5, R Manfredini5,
C Romualdi1, P Guglielmelli4, AM Vannucchi4,7 and S Bortoluzzi3,7 on behalf of the Associazione Italiana per la Ricerca sul Cancro
Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators8
microRNAs (miRNAs) are relevant in the pathogenesis of primary myelofibrosis (PMF) but our understanding is limited to specific
target genes and the overall systemic scenario islacking. By both knowledge-based and ab initio approaches for comparative analysis of
CD34+ cells of PMF patients and healthy controls, we identified the deregulated pathways involving miRNAs and genes and new
transcriptional and post-transcriptional regulatory circuits in PMF cells. These converge in a unique and integrated cellular process, in
which the role of specific miRNAs is to wire, co-regulate and allow a fine crosstalk between the involved processes. The PMF pathway
includes Akt signaling, linked to Rho GTPases, CDC42, PLD2, PTEN crosstalk with the hypoxia response and Calcium-linked cellular
processes connected to cyclic AMP signaling. Nested on the depicted transcriptional scenario, predicted circuits are reported,
opening new hypotheses. Links between miRNAs (miR-106a-5p, miR-20b-5p, miR-20a-5p, miR-17-5p, miR-19b-3p and let-7d-5p) and
key transcription factors (MYCN, ATF, CEBPA, REL, IRF and FOXJ2) and their common target genes tantalizingly suggest new path
to approach the disease. The study provides a global overview of transcriptional and post-transcriptional deregulations in PMF, and,
unifying consolidated and predicted data, could be helpful to identify new combinatorial therapeutic strategy. Interactive PMF network
model: http://compgen.bio.unipd.it/pmf-net/.
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INTRODUCTION
Primary myelofibrosis (PMF) is a chronic myeloproliferative neoplasm
(MPN) that, with essential thrombocythemia and polycythemia
vera, constitutes a heterogeneous group of Philadelphia-negative
clonal hematopoietic stem cell (HSC) disorders associated with
overproduction of mature myeloid cells. Typical traits of myelofi-
brosis are an increased proliferation of megakaryocytes, a deposition
of fibrosis in the bone marrow, an abnormal stem cell trafficking and
an extramedullary hematopoiesis (myeloid metaplasia). Moreover,
PMF is associated with an increased risk of thrombosis and/or
hemorrhage and a propensity to develop acute myeloid leukemia.1,2
Important progresses in molecular characterization of MPNs
pathogenesis have been done in the last years. Specifically,
the discoveries of somatic mutations in JAK2, MPL and CALR
genes have improved patients’ stratification and molecular
characterization highlighting the role of Jak-STAT signaling in
MPN pathogenesis. However, several evidences indicate that these
mutations are not sufficient for disease initiation and progression
and that the phenotypes of the disease are highly heterogeneous,
suggesting that other unknown genetic or epigenetic factors
might be involved3–15 and also that the mutation order could
matter:16 driver mutations can precede or follow additional
somatic mutations in other myeloid genes. Interestingly, recently,
it has been demonstrated that most of these genes are associated
with age-related clonal hematopoiesis in normal elderly subjects,
suggesting that pre-malignant clones may be present many
years before disease develops and are required, but insufficient, to
result in disease.17,18
microRNAs (miRNAs) have an important role in the regulation
of hematopoiesis.19–22 Our group demonstrated that miR-16-2
contributes to the expansion of erythroid lineage in polycythe-
mia vera23 and we showed that miR-155-5p is pathogenically
associated to MK hyperplasia in PMF through JARID2
downregulation.24 Moreover, we recently characterized miRNA
and microRNA offset RNAs (moRNA) expression in SET2 cells25
and in CD34+ stem cells using massive small RNA-seq.
In the latter study, we observed specificities in small RNAs
expression of PMF cells.26 Although these findings are suppor-
tive of the involvement of miRNAs in PMF pathobiology, our
understanding of miRNAs involvement in MPNs is still limited.27
A deeper characterization of the miRNA-mediated pathogenesis
processes19,28 would be highly desirable in order to identify
suitable concurrently targetable pathways amenable to ther-
apeutic intervention.28,29
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Thereby, the aim of this study was to obtain an informative,
composite and interactive data-driven picture of pathways
and circuits deregulated in PMF. We used a composite pipeline
exploiting both ‘knowledge-based’ and ab initio approaches to
discover mixed transcriptional and post-transcriptional deregu-
lated circuits in PMF. This strategy allowed us to describe an
unforeseen picture of miRNA and gene regulatory circuits linked
to abnormal cellular functions and pathways.
METHODS
Patient selection and expression data
For this study, we considered miRNA and gene expression data (series
GSE41812 and GSE53482) obtained by analyzing CD34+ cells of 42 patients
with a diagnosis of PMF and 16 peripheral blood (CTR PB) and 15 bone
marrow (CTR BM) samples from normal donors. Primary myelofibrosis
patients were in a typical fibrotic stage of the disease according to the WHO,
and were molecularly characterized (JAK2V617F, MPLW51 and CALR muta-
tions). See Norfo et al.24 for additional clinical information about patients.
Gene expression profiling, obtained by Affymetrix HGU219, and annotated
by using custom CDF,30 HGU219_Hs_ENTREZG version 14, was normalized
by RMA procedure. A log2 expression matrix with 18 654 genes and 73
samples was obtained.
MiRNA expression profiling, obtained by Affymetrix miRNA 2.0 micro-
array, was analyzed by using a modified RMA procedure: the background
subtraction was performed considering all species and controls of the chip,
while normalization and summarization were calculated only on human
probe sets, using a custom-designed CDF. MiRNA names were translated to
updated miRBase names filtering out deprecated miRNAs, using the
custom annotation package AffyIDs. A log2 expression matrix of 584
miRNAs and 73 samples was obtained after filtering miRNAs weakly
expressed (lowest 25% of average expression level) and/or poorly variable
across samples (Shannon Entropyo1.4).
Identification of negatively correlated predicted targets of miRNAs
We identified the predicted regulatory relations supported by our
expression data by integrating target predictions and expression profiles.
Target predictions were computed with TargetScan-62 algorithm accord-
ing sequence similarity with conservation (threshold at 0.8).
Pairwise Pearson correlations between miRNA and predicted target
gene expression profiles were calculated. The relationships supported
by significant anti-correlation (ro−0.5 with FDRo0.1) were considered for
the following analyses.
The miRNA/target interactions involving genes annotated in KEGG
pathways have been used in the following Micrographite pipeline.
Pathways-derived circuits
Two comparisons were considered for the analysis: PMF vs CTR BM and PMF
vs CTR PB. mRNA and miRNA relations involved in PMF were compared to
CTR PB or CTR BM and have been identified using the Micrographite pathway
analysis.31 In the following we will report a brief description of the main steps
of the method; for details refers to Calura et al.31
KEGG32 pathways as stored in graphite Bioconductor package33 were
enriched with validated and predicted miRNA-target interactions. We consider
‘validated interactions’ those interactions extracted from miRTarBase34 and
miRecords35 for which reporter assays have been provided in literature, while
the ‘predicted/supported interactions’ are the in silico predicted miRNA-mRNA
couples filtered by anticorrelation of expressions as discussed above. In this
step, only miRNAs targeting genes already annotated in the cell pathways
have been added. Following the Micrographite pipeline, the pathways resulted
to be significant at the whole pathway level (q-value for the mean and
variance testso =0.1) were used for the second step of the analysis that
identifies, within each significant pathway, the subportion of the pathway
(hereafter called path) mostly associated to the phenotype. The merge of the
top 10 paths is called meta-pathway. The meta-pathway is then re-analyzed in
order to find the top scored paths. Finally, the paths that, ranked by scores,
belong to upper quartile are considered as the most involved and reported.
The Micrographite analysis has been performed independently for each
comparison (PMF vs CTR PB; PMF vs CTR BM) and the two final networks have
been merged into a single network.
Mixed miRNA-TF-gene circuit identification
In parallel, the expression data of genes that are present in the KEGG
pathways were used with the miRNAs profile as input of Magia2. Magia2
(http://gencomp.bio.unipd.it/magia2)36 reconstructs circuits involving posi-
tive and negative correlations between miRNAs, transcription factors (TFs)
and target genes. It uses experimentally validated TF–miRNA relations
obtained by mirGen2.0 and TransmiR, and TF-gene relations obtained by
the UCSC human genome annotation.
Target predictions were computed with TargetScan (score threshold at
0.8, top 25% of the predictions distribution) and Pearson’s correlation
coefficient was used as correlations measure (threshold at 0.5).
Pathways visualization
Network visualization and annotation have been performed using
Cytoscape37 (version 3.1).
Validation of differentially expressed sRNAs
We performed individual miRNAs assay by Taqman quantitative real-time
PCR for quantification of abnormally expressed miRNAs in PMF and control
granulocytes and plasma. All samples were processed within 4 h after
collection. Plasma, collected by peripheral blood centrifugation in tubes
containing EDTA (4 °C, 3000 revolutions per minute for 15 min, then 6000
revolutions per minute for 5 min), was stored at -80 °C in RNase/DNase-free
Eppendorf tubes. RNA was isolated and eluted in 20 μl of RNase-free water
using a miRNeasy Serum/Plasma Kit (Qiagen). For miRNA expression assays
8 μl eluted RNA was used.38 cDNA was synthesized from total RNA using
miRNA-specific RT primers contained in the TaqMan microRNA Human
Assays (Applied Biosystems, Foster City, CA, USA). Briefly, single-stranded
cDNA was synthesized from 10 ng total RNA in 15-μl reaction volume with
the High-Capacity cDNA Archive Kit (Applied Biosystems) using 1 mM
deoxyribonucleoside triphosphates, 50 U Multiscribe reverse transcriptase,
3.8 U RNase Inhibitor and 50 nM of miR-specific RT primers. The reaction was
incubated at 16 °C for 30 min followed by 30 min at 42 °C, and inactivation
at 85 °C for 5 min. Each generated cDNA was amplified by quantitative real-
time-PCR with sequence-specific primers from the TaqMan microRNA Assays
on an ABI Prism 7300 real-time PCR system (Applied Biosystems). PCR
reactions included 10 μl 2 × Universal PCR Master Mix (No AmpErase UNG),
2 μl each 10× TaqMan MicroRNA Assay Mix and 1.5 μl reverse-transcribed
product; they were incubated in a 96-well plate at 95 °C for 10 min, followed
by 40 cycles of 95 °C for 15 s and 60 °C for 1 min. Expression variations were
calculated using the RQ method and a t-test P-value of 0.05 was used as
threshold to identify differentially expressed elements.
RESULTS AND DISCUSSION
A systems biology pipeline identifies deregulated signaling
pathways in PMF patients
We considered matched expression profiling data of 584 miRNAs
and 18 654 genes in 73 CD34+ cells sampled from 42 PMF patients,
and 31 sampled from normal subjects (15 from bone marrow
(CTR BM) and 16 from peripheral blood (CTR PB). The study grounds
on comparative analysis of CD34+ cells of PMF patients compared
with control CD34+ from normal donors. In a previous study,
specificities of both gene and miRNA expression profiles were
observed comparing peripheral blood and bone marrow control
samples,24 confirming known differences between these popula-
tions. Thus, peripheral blood and bone marrow control samples
were considered separately, for parallel comparisons with PMF
samples, to avoid biases due to control samples inhomogeneity,
and to obtain more informative results. Then, a union of the
comparisons gave a global picture. The flowchart in Figure 1
provides a summary of the procedure.
We obtained 250 interactions in the PMF vs CTR BM (54 miRNAs
and 236 gene targets involved) and 442 in the PMF vs CTR PB
(43 miRNAs and 428 genes) using MAGIA2. Then, the miRNA and
gene expression profiles of PMF patients have been indepen-
dently compared with CTR BM and CTR PB health samples using
Micrographite. Supplementary Tables 1-8 contain all the inter-
mediate data of the two analyses whereas a brief comparison of
results is summarized in Supplementary Figures 1 and 2. The
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resulting networks of the two analyses were merged achieving a set
of 181 non-redundant genes and miRNAs and their interactions that
represent the compendium of the deregulated pathway-guided
interactions in PMF. The network contains a selection of 401 gene-
gene consolidated interactions from KEGG pathways, 45 miRNA-gene
connections already validated with gene reporter assays and only one
in silico predicted anti-correlated miRNA-gene connection (Figure 2a).
See http://compgen.bio.unipd.it/pmf-net/ for an interactive, search-
able and zoomable version of the PMF network model.
Mixed miRNA-TF circuits connect to altered pathways
miRNAs post-transcriptionally regulate gene expression, also by
alteration of target mRNAs stability. Moreover, TFs modulate the
expression of miRNAs and of target genes at transcriptional level,
creating a regulatory network. Magia2 analysis identified mixed
regulatory circuits composed of miRNAs, TFs and target genes,
considering in parallel expression profiles in PMF and CTR BM
samples and in PMF and CTR PB samples. For each type of control
samples used, Supplementary Tables 9–12 report more details on
observed correlation values, on the numbers of identified circuits,
on predicted interactions and on involved genes and miRNAs.
Inferred interplay of miRNAs and TFs in gene/transcripts expression
regulation may comprise two types of mixed regulatory circuits:
(i) a TF regulates both a miRNA and a gene promoter, and the
same miRNA targets the gene mRNA exerting post-transcriptional
regulation; (ii) a miRNA post-transcriptionally regulates both a gene
encoding a TF and another gene, that on turn is a transcriptional
target of the TF. For both mixed circuits topologies, different
combinations of positive and negative pairwise correlations should
correspond to activatory and inhibitory interactions giving rise
to coherent or incoherent feed forward loops.36,39 Since circuits
based on strongest interactions are particularly trustable and may
highlight key regulatory relations, we focused on circuits that
had absolute correlation at least 0.5 for all the three types of
interactions (miRNA-target gene, TF-miRNA, TF-target-gene). PMF vs
CTR PB comparison identified 169 interactions, involving 63 nodes,
6 miRNAs and 57 genes. No significant circuits were selected for
PMF vs CTR BM comparison.
Pathway annotations are progressively manually updated but,
even if enriched with miRNA validated interactions, they are still
incomplete. Thus, we enriched the pathway-based networks
with nodes and relations coming from selected Magia2 circuits,
that shared with the first network at least one gene or one miRNA.
In this way, we obtained the network, consisting of 620 edges and
220 nodes (of which 34 are miRNAs; Table 1); they are reported,
with different details and annotation, in Supplementary Figure 3
and are included in the yellow area of the circuit in Figure 2a.
Table 1 summarizes miRNAs and TFs involvement. Magia2 circuits
showed that six miRNAs and six TFs seem to play critical roles in the
regulation of transcription in PMF (Figure 2a and Table 1). Almost all
of the miRNAs are components of miR-17 family (miR-106a-5p,
miR-20b-5p, miR-20a-5p, miR-17-5p and miR-19b-3p). The upregula-
tion of the latter miRNA in PMF CD34+ cells has been previously
validated.24 Only let-7d-5p is a component of another family of
miRNAs, the let-7 family, which is present also inMicrographite results.
The TFs (MYCN, ATF, CEBPA, REL, IRF and FOXJ2) are important
regulators of several target-genes. Relevant contribution in PMF vs
CTR PB comparison is done by MYCN gene, in particular the
upregulation of the miR-17 family components and the down-
regulation of let-7d-5p. The bridge elements between the pathway
network and predicted circuits are two miRNAs (miR-17-5p and
miR-20a-5p) and four genes (ATF, CREB5, NRAS and ARHGEF7).
Different genetic lesions characterizing PMF patients (28 JAKV617F,
7 CALR, 4 MPLW51 and five triple negative, 3N, for the former
mutations) included in this study are representative of the molecular
alterations described in PMF. Given such patient heterogeneity,
we checked if some of the genes/miRNAs modulated in PMF were
deregulated only, or mainly, in a subgroup of patients. As shown
in Figure 2b, and in Supplementary Figure 4, cluster analysis of
samples based on expression profiles of miRNAs and genes included
in the PMF network of Figure 2a did not highlight any correlation
with the presence of a specific mutation. Therefore, results of cluster
analysis suggest that our results provide a comprehensive picture of
Figure 1. Experimental design and analysis procedures flow chart. miRNA and gene expression data in CD34+ cells of PMF patients and
healthy controls were considered; CTR BM and CTR PB controls were considered separately in parallel analyses, and results were merged at the
final steps. MAGIA integrated analysis outputted the subset of predicted miRNA-target relations supported by expression data; these were
used to enrich KEGG pathway-derived miRNA-gene networks based on pathways annotations and on validated miRNA-target relations.
Topological pathway analyses by Micrographite identified most modulated paths, showing significant gene/miRNA expression variations and
changes in relations strength, then a non-redundant comprehensive meta-pathway was derived; iterative analysis of the meta-pathway
identified the most modulated network for each comparison. Magia2 analysis identified mixed TF-miRNA-gene circuits. Results of parallel
comparisons were merged in an integrated network.
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Figure 2. PMF network model. (a) PMF network integrating pathway-derived miRNA-gene networks deregulated in PMF and mixed TF-miRNA-gene
circuits discovered by reverse engineering of expression data. The network (see Supplementary Figure 3 for a larger version) gives a non-redundant
and comprehensive picture of most modulated paths in the two PMF vs CTR comparisons, of the impact of miRNAs on pathway genes, and of
connected TF-miRNA-gene mixed circuits discovered in the study. Genes are reported as round rectangles, transcriptional factors as diamonds and
miRNAs as triangles. Node colors represent the fold-change (FC) of the gene expressions in the PMF vs CTR BM (node inner color) and PMF vs CTR PB
(node border color). The type of edges depends on the type of interaction: arrow for activation, T arrow in case of inhibition, and arrow line for miRNA-
target predicted/supported interactions. The light blue shade indicates the part of the network resulting from miRNA and gene topological pathway
analysis. The yellow shade indicates mixed TF-miRNA-gene circuits, inferred by Magia2 analysis, connected to the path-derived network. (b) Cluster
analysis of expression profiles of miRNAs and genes included in the final PMF network do not show clustering of PMF patients by mutation. Samples
are colored according to the carried mutation as shown in the legend (3N indicates triple negative). Sample clustering was obtained according to
Euclidean distance and complete clustering. See Supplementary Figure 4 for the corresponding heatmap. (c) Summary of most deregulated pathways
represented in the miRNA-gene network, and connections thereof. See http://compgen.bio.unipd.it/pmf-net/ for an interactive, searchable and
zoomable version of the PMF network model.
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deregulated elements and relations thereof, that are common to
all PMF patients, independent of the underlying driver mutation.
Accordingly, fold-changes against control cells have been recalculated
stratifying patients by driver mutations; these data do not show
mutation-specific contributions in the here presented network
(Supplementary Figure 5).
Confirmation of miRNA and gene differential expression in PMF
Genes and miRNAs are included in the PMF network only if they
have shown coordinated expressions across patients and opposite
behaviors if compared to healthy donors. Specifically, modulated
genes and miRNA are included in the PMF network if they are
either linked according to validated relations (pathway-derived
part of the network and TF-gene or TF-miRNA relations in the part
containing MAGIA2 circuits) or linked by predicted miRNA-target
relations that are anyway significantly supported by expression
data analysis.
Even if the multistep approach we used for the PMF network
reconstruction was specifically designed to go beyond the differential
expression of single genes or miRNAs, giving a more informative
picture of the impact of miRNAs deregulated in PMF to pathways and
to mixed connected regulatory circuits it is worth noting that we
obtained confirmation of the differential expression in PMF samples
compared to controls for 13 miRNA and 5 genes included in the
network, giving further support to our results. As detailed in Table 2,
in addition to the confirmation of differential expression in CD34+
previously obtained by array and quantitative real-time-PCR24 and
RNA-seq,26 we also conducted new experiments in granulocytes
and plasma (see Methods) to obtain new insights of direct
translational relevance. These confirmed a significant upregulation
(P-valueo0.05) of miR-195-5p, miR-106a-5p, miR-145-5p, miR-17-
5p, miR-185-5p, miR-195-5p in PMF patients granulocytes (GR;
considering 50 PMF patients and 10 healthy controls), miR-19b-3p
both in PMF granulocytes and plasma (25 PMF patients and
6 controls) and of miR-29b-3p in plasma.
Candidate transcriptional deregulated pathways of PMF
Figure 2c summarizes the main alterations of the transcript levels
observed in PMF patients, involving key pathways and connected
circuits, as discussed below in more detail with the support of
Figure 3.
Akt signaling. One of most deregulated pathways is the Akt
signaling, a part of the Phosphoinositide-3 kinase/protein kinase-B/
mammalian target of Rapamycin (PI3K/Akt/mTOR) pathway
(Figure 3a). As the Jak/STAT signaling path, the Akt signaling is
triggered by receptor tyrosine kinases that increase PI3K levels,
activating AKT, phosphorylating several targets including mTOR.
Several tumor suppressor genes, as PTEN, interact with this path.
PI3K/AKT/mTOR is a central signaling module and several other
pathways converge on it regulating cell survival and proliferation.28
It is constitutively activated in MPNs and also in other cancers.28
Small molecular inhibitors of this pathway are available in clinics,23
and evidence of activity of an mTOR inhibitor (Everolimus) in
myelofibrosis patients has been provided.40 The contribution of
PI3K/mTOR pathway to MPN pathogenesis has received strong
experimental support.28,41,42
Rho GTPases, CDC42, PLD2 and PTEN. The PMF network shows
deregulation of Rho GTPases (Figure 3b), intracellular signal
transducers, members of the RAC subfamily of Rho GTPases.
Deregulation of GEFs (guanine nucleotide exchange factors),
recharging Rho GTPases and determining their spatial-temporal
activity is also displayed. Interaction of stem cell factors
and adhesion molecules with their receptors (c-Kit, CXCR4
and Integrins) expressed by the HSCs triggers the activation of
GEFs.43 Rho GTPases could affect also cancer progression,44 both
as oncogene and oncosuppressor. Specifically, CDC42 and RAC2
control homeostasis of blood cell production by hematopoietic
stem/progenitor (HSC/P) cells balancing HSC/P retention within
the bone marrow and migration in the blood.45
CDC42, highly downregulated in PMF,20 regulates cell polarity
and cell cycle progression. Its deletion affects the number of early
myeloid progenitors while suppressing erythroid differentiation.46
CDC2-deficient mice develop a fatal myeloproliferative disorder
manifested by significant leukocytosis with neutrophilia, myeloid
hyperproliferation and myeloid cell infiltration into distal organs.46
Downregulation of RhoA activity, as observed in PMF, resulted in
increased HSC engraftment and self-renewal. In the network,
CDC42 is connected with the upregulated miR-29a-3p, which
we previously demonstrated is able to suppress their expression24
and which is connected also to the phosphatase PTEN, regulated
by RhoGTPases.47 In turn, PTEN, down-regulated in PMF (and linked
to several miRNAs including the upregulated miR-19a-3p, miR-29a-
3p and miR-21-5p), modulates intracellular levels of PI3K in cells,
functioning as a tumor suppressor. The upregulation in PMF of
miRNAs interacting with PTEN was previously established.24 CDC42
Table 1. miRNAs impacting in pathway-derived miRNA-gene
networks deregulated in PMF and participating to mixed TF-miRNA-
gene circuits
Main pathways and genes miRNAs
Ca(2+) signaling miR-125b-5p
miR-133a
CDC42 miR-185-5p
miR-29b-3p
miR-29c-3p
HIF-1 alpha hypoxia pathway miR-1244
NF-kappaB signaling miR-124-3p
miR-146a-5p
miR-146b-5p
PTEN signaling miR-106b-5p
miR-19a-3p
miR-20a-5p
miR-21-5p
miR-221-3p
miR-222-3p
miR-26a-5p
miR-494
miR-519d
miR-93-5p
PTEN-GEF crosstalk miR-17-5p
PTEN-CDC42 crosstalk miR-29a-3p
RAS-PTEN crosstalk miR-217
RAS/RAS signaling miR-195-5p
miR-7-5p
let-7a-5p
miR-122-5p
miR-126-3p
miR-145-5p
RAS/RAF signaling, GEF activity let-7d-5p
RHOA miR-31-5p
RHOA, MAPK and NF-kappaB signaling miR-155-5p
Transcription factors miRNAs
MYC miR-19b-3p
ATF2, CEBPA, MYC let-7d-5p
FOXJ2, MYC, IRF1 miR-106a-5p
FOXJ2, MYC miR-20b-5p
REL, CEBPA, FOXJ2, MYC, IRF1 miR-17-5p
Abbreviations: miRNA, microRNA; PMF, primary myelofibrosis; TF, transcription
factor. The upper part of the table indicates the pathways or genes targeted
by miRNAs in PMF; the lower part of the table indicates the transcription
factors for which the interplay with miRNAs has been in silico inferred.
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is also connected with miR-29b-3p, miR-29c-3p and miR-185-5p, the
latter linked also with the downregulated RHOA.
Another element markedly deregulated in the PMF network
is Phospholipases D, PLD1 and PLD2 (Figure 3b). Phospholipase D
and its product PA (Phosphatidic Acid) have been implicated in
many physiological and pathological functions, such as cancer cell
invasion and metastasis.48–52 PLD2 is dual activity enzyme with
both lipase and GEF activities for the Rac2 and RhoA GTPases.
As demonstrated by Mahankali et al,53 in the context
of leukocyte chemotaxis, both activities are triggered after cell
stimulation, but then, the accumulation of RAC2-GTP, due to GEF
action, negatively feeds back on PLD2-lipase activity, and the
JAK3 tyrosine kinase restores lipase activity while ultimately
inhibiting GEF activity.54 This lipase-GEF duality has important
biochemical and cellular implications and new PLD inhibitors have
been recently described.52,54 PA is one of the major lipid second
messengers that in turn triggers many signaling pathways such as
PI3K/Akt/mTOR, sphingosine kinase 1, Raf-1 protein kinase53 and
small GTPases like Ras and Rac.55
HIF-1a pathway. In connection with previously mentioned path-
ways, we found evidence of modulation of the HIF-1a hypoxia
pathway (Figure 3c). As known, both growth factors and
oncogenic signaling can trigger an HIF-1a response, with the
PI3K/Akt and Ras/Raf/MAPK pathways mediating upregulation of
HIF-1a by increasing HIF-1a protein synthesis or stability, resulting
in a modified transcriptional activity of HIF-1. In our network,
the predicted/supported relation of the still poorly characterized
miR-1244 (downregulated in PMF) with NOS3 (nitric oxide
synthase 3, endothelial cell) is connected with HIF-1a while the
upregulated miR-20a-5p connects HIF-1a to PTEN. NOS3 synthe-
sizes nitric oxide, that is involved in several processes such as
muscle relaxation, inhibition of platelet aggregation and leukocyte
adhesion, with both vasodilatatory and antithrombotic properties.
A recent study showed that NOS3 Glu298Asp polymorphism in
homozygosis increased the risk of thrombosis in a cohort of
patients with essential thrombocythemia or prefibrotic PMF.56,57
A link between hypoxia and the activation of the HGF/Met axis,
through the oxygen sensor HIF-1a in MPNs, has recently been
proposed by Boissinot and colleagues.58 Oxygen tension is as
low as 1% in normal bone marrow59 and the hypoxic condition
may result even more stringent because of the bone marrow
hypercellularity in myelofibrosis. In accordance with our results,
showing activation of the HIF-1a downstream genes (Figure 3c)
and of NF-κB signaling (Figure 3a), the authors proposed that the
activation of the HGF/Met axis, due to bone marrow or/and
exposure to inflammation cytokines (NF-κB-mediated activation),
leads to enhanced survival and proliferation of mutated myeloid
progenitors and increased production of various cytokines
responsible for inflammation, neo-angiogenesis and fibrosis. Thus,
molecules efficient at blocking NF-κB and HIF-mediated activation
might represent an efficient therapy for MPNs by simultaneously
blocking the cascade of inflammation cytokines, their signaling
and the hematopoietic clone.
Calcium and cyclic AMP signaling. The upper part of the network
in Figure 2a includes genes, belonging to Calcium signaling
path (Figure 3d). More specifically, this part of the network
includes genes encoding several subunits of calcium channel
voltage-dependent, and other genes, including ATF/CREB subunits
activated by cyclic AMP-dependent protein kinases, tightly related
to MAPK and Ras signaling pathways, Chemokine signaling and
Apoptosis. ATF/CREB genes participate also to PI3K/Akt signaling
pathway and to TNF signaling pathway. The Calcium, and
c-AMP networks include, as possible modulators, miR-125b-5p
(that might target the downregulated PPP1CA and GRIN2A) and
miR-133a (that might target CACNA1C).
CALR mutations are found in PMF and essential thrombocythemia
patients. Calreticulin is a multifunctional protein that acts as a major
Ca2+-binding (storage) protein and chaperone in the lumen of the
endoplasmic reticulum and intervene in transcription regulation.60
CALR has been implicated in the development of different cancers
and its effect on tumor formation and progression may depend on
cell types and clinical stages.60 CALR is not differentially expressed in
Table 2. miRNAs and genes included in the network for which differential expression in PMF patients compared to healthy controls has been
confirmed
PMF vs CTR CD34+ GR and Plasma
Arrays RNA-seq RT-PCR RT-PCR (PMF vs CTR; RQ mean± dev)
miR-106a-5p UP UP GR (1.9± 1.2 vs 1.08± 1.0)
miR-145-5p UP UP GR (1.7± 0.9 vs 1.0± 0.5)
miR-146b-5p UP UP
miR-155-5p UP UP
miR-17-5p UP UP GR (1.5± 0.7 vs 1.1± 0.9)
miR-185-5p UP UP GR (3.0± 3.1 vs 1.5± 1.2)
miR-195-5p UP UP UP GR (15.3± 10.5 vs 1.8± 2.1)
UP Plasma (12.4± 17.5 vs 1.37± 0.95)
miR-19a-3p UP UP UP GR (15.3± 10.5 vs 1.8± 2.1)
UP Plasma (12.4± 17.5 vs 1.37± 0.95)
miR-19b-3p UP UP UP
miR-21-5p UP UP
miR-29a-3p UP UP UP UP Plasma (3.0± 3.1 vs 1.5± 1.2)
miR-29c-3p UP UP
miR-494-3p UP UP UP
ANGPT1 UP UP
ARHGEF7 DOWN DOWN
CDC42 DOWN DOWN
MEF2D DOWN DOWN
SMAD7 DOWN DOWN
Abbreviations: miRNA, microRNA; PMF, primary myelofibrosis. The second column indicates if miRNAs and genes resulted up- or down-regulated according to
array data used for network reconstruction. The following columns indicate for which elements a significant differential expression has been previously
confirmed using RNA-seq in CD34+ cells,22 and using RT-PCR in CD34+ cells,20 in granulocytes (GR) and in plasma samples.
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PMF compared to controls and not present in the network
(PMF equal to CTR PB controls and only slightly upregulated in
PMF in comparison to CTR BM controls) evidencing that genetic
alterations of PMF patients do not affect significantly the
transcriptional behavior of the CALR gene. However, many CALR
interactors and genes participating in CALR-involving pathways
are represented in the PMF network: ATF4 and ATF6 participate
to unfolded proteins response (Protein processing in endoplasmic
reticulum), and transduce to the nucleus ER stress, eventually
inducing apoptosis; CD209 and RAC1 participate to the Phagosome;
several genes, including FOS/JUN and NFKB are in the Chagas
disease path; ATF2/CREB, NFAT, EP300 and RAS genes share with
CALR the HTLV-1 infection path.
The Ca2+-related part of the net is connected to the TFs ATF2
and CREB. Several circuits show cross-talk of ATF2 and let-7d-5p,
both downregulated in PMF, to 12 correlated genes, mostly
downregulated in PMF (RNF7, HIC1, HIC2, PRKACG, PRKX, PRKACA,
PRKACB, MEF2D, ARMC8, KLF9, ZNF516). Among them HIC1/2
are tumor suppressor genes,61 known to be hypermethylated in
cancer and in high-risk myelodisplastic syndromes;62 ZNF516 is a
zinc-finger protein that interacts with epigenetic regulation protein
such as HDAC1 and KDM1A. The upregulated PLXND1 is one
of Semaforin receptors, often highly expressed in cancer,63 that
regulates tumor cell survival by suppressing an apoptotic pathway64
and seems to controls angiogenesis in cancer.65 let-7d-5p has
also correlated expression with MYC with which its shares KLF13 as
putative target. CREB connects to miR-20a 5p and to MYC, and in
turn to their common targets.
Predicted circuits open new hypotheses
All the deregulated pathways contain links to novel in silico
predicted interactions that could help in the candidate selection
in research. In support of the results consistency, a subset of
de novo predicted interactions is known and validated, that is,
the upregulated miR-17-5p, miR-106a-5p and miR-20b-5p with the
downregulated CDKN1A. CDKN1A is an important intermediate
by which p53 blocks proliferation in response to DNA damage,
and it inhibits CDK activity, blocking cell cycle progression. The
validated post-transcriptional regulatory relations are also linked
to MYC (highly upregulated in PMF) transcriptional activity, which
is known to stimulate the expression of onco-miR-17 family. These,
Figure 3. Details of the PMF network model showing deregulated miRNAs and genes that participates to specific connected pathways, linked
in turn to biological processes and functions germane to the disease. (a) Akt signaling; (b) Rho GTPases, CDC42, PLD2 and PTEN; (c) HIF-1a
pathway; (d) Calcium signaling.
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in turn suppress IRF1, a tumor suppressor TF that is downregulated
in PMF and has important supported targets, as MAP3K2, GLIS3 and
LRCH1, all downregulated.
Four upregulated miRNAs (miR-17-5p, miR-106a-5p miR-20a-5p
and miR-20b-5p) are negatively correlated with the downregulated
TF FOXJ2 (Forkhead box protein J2), forming triangular circuits
with four genes including the upregulated PDZ and LIM domain 5
(PDLIM5), recently identified as the main signaling molecule that, in
the context of augmented AMPK activity and in connection with
Rac1-mediated acting cytoskeleton reorganization,66 regulates cell
migration, a key process in MPNs.
CONCLUSIONS
The network inferred in this work is a unique and integrated
signaling pathway of PMF, in which the role of miRNA is to wire,
co-regulate and allow a fine crosstalk between all the involved
processes. Most deregulated pathways include Akt signaling, linked
to Rho GTPases, CDC42, PLD2 and PTEN crosstalk with the hypoxia
pathway, which highlights the extreme hypoxic status in PMF bone
marrow. Novel hints on cyclic AMP signaling involvement jointly
connected with Calcium-linked cellular processes were given. More-
over, mixed circuits involving miRNAs (miR-106a-5p, miR-20b-5p,
miR-20a-5p, miR-17-5p, miR-19b-3p and let-7d-5p) connections
with key TFs (MYCN, ATF, CEBPA, REL, IRF and FOXJ2) and their
common target genes were reported, opening new hypotheses.
The comprehensive picture of transcriptional deregulation can
be used to improve current understanding of the molecular
pathways involved in the disease and delineate new combinatorial
therapeutic strategies.
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